Clarivate’s Epidemiology's coverage of heart failure (HF) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed event…
PAH is a rare, life-threatening disorder marked by considerable morbidity and mortality. Despite the availability of a wide array of drugs for PAH, substantial unmet need remains for more-…
Drug treatment of chronic heart failure (CHF) with reduced ejection fraction (HFrEF) is well established with a wealth of supporting evidence from clinical trials. ACE inhibitors or ARBs, beta…
First-line treatment of chronic heart failure (CHF) usually involves an angiotensin-converting enzyme (ACE) inhibitor, an oral beta blocker, and an oral diuretic. The addition of a second- or third…
Despite heart failure with preserved ejection fraction (HFpEF) accounting for approximately half of all chronic heart failure (CHF) cases, and despite our improved understanding of the…
Drug treatment of chronic heart failure with reduced ejection fraction (HFrEF) is well-established with a wealth of supporting evidence from clinical trials. ACE inhibitors or AIIRA/ARBs, beta…
First-line treatment of chronic heart failure (CHF) usually involves an angiotensin-converting enzyme (ACE) inhibitor, an oral beta blocker, and an oral diuretic. The addition of a second- or third…
Heart failure with preserved ejection fraction (HFpEF) occurs due to abnormal relaxation and filling of the left ventricle. Despite the fact that HFpEF accounts for nearly half of all CHF cases,…
A comprehensive, quantitative understanding of patient progression through all stages of disease management and treatment is critical in both assessing a market opportunity within a therapeutic…
Market Outlook This report examines the market access factors that influence the success of therapies for chronic heart failure (CHF), with a special focus on payers’ and cardiologists’…
Patients with chronic heart failure (CHF) are subject to high rates of mortality and morbidity. Consequently, treatment rates in CHF are high. The treatment algorithm for CHF is well established…
Chronic heart failure (CHF) describes the long-term management of heart failure outside the hospital setting. CHF patients are subject to high rates of mortality and morbidity. Frequent…
Treatment of heart failure with reduced ejection fraction (HFrEF) is well-established with a wealth of evidence from clinical trials that support the use of all standard-of-care therapies for CHF…
First-line treatment of chronic heart failure (CHF) usually involves a beta blocker, an angiotensin-converting enzyme (ACE) inhibitor, and an oral diuretic. Second- or third-line treatments are…